CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase I drugs for Metastatic Ovarian Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CUE-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CUE-102 overview

CUE-102 is under development for the prevention of synovial sarcoma, head and neck cancer, melanoma, prostate cancer, acute myelocytic leukemia, ovarian cancer, endometrial cancer, breast cancer, lung cancer, gastric cancer, gastroesophageal (GE) junction Carcinomas, pancreatic cancer and colorectal cancer. It is administered through intravenous route as injection. It is composed of IL-2 and a pMHC complexed with a dominant peptide derived from the from the Wilms’ Tumor protein. It is developed using Immuno-STAT technology. The drug candidate targets WT1 and interleukin 2 receptor.

Cue Biopharma overview

Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse. CUE-200 series to give a boost to exhausted T cells and CUE-300 series. It offers therapy in areas of immuno onncology, infectious diseases and autoimmune diseases. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, is designed to regulate the body’s intrinsic immune system. The company also provides clinical trails and research services. Cue Biopharma is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of CUE-102’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.